Medscape18h
B-Cell Depleting Drug Shines in IgG4-Related Disease
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
MedPage Today3d
NMO Drug Looks Good for IgG4-Related Disease
WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual ...
Amgen’s Uplizna shows potential efficacy in rare inflammatory diseases
Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...
Zenas BioPharma’s Promising Pipeline and Strategic Moves Earn Buy Rating
Zenas BioPharma, Inc. (ZBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
Citi initiates coverage on 5 new biotech stocks
Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...